Logo image of NUVB

NUVATION BIO INC (NUVB) Stock Price, Quote, News and Overview

NYSE:NUVB - New York Stock Exchange, Inc. - US67080N1019 - Common Stock - Currency: USD

2.25  +0.22 (+10.84%)

After market: 2.2012 -0.05 (-2.17%)

NUVB Quote, Performance and Key Statistics

NUVATION BIO INC

NYSE:NUVB (5/22/2025, 8:04:01 PM)

After market: 2.2012 -0.05 (-2.17%)

2.25

+0.22 (+10.84%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High3.97
52 Week Low1.54
Market Cap764.26M
Shares339.67M
Float247.61M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/amc
IPO07-01 2020-07-01


NUVB short term performance overview.The bars show the price performance of NUVB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

NUVB long term performance overview.The bars show the price performance of NUVB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20

The current stock price of NUVB is 2.25 USD. In the past month the price increased by 5.63%. In the past year, price decreased by -26.95%.

NUVATION BIO INC / NUVB Daily stock chart

NUVB Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 51.98 678.00B
JNJ JOHNSON & JOHNSON 15.19 367.19B
NVO NOVO-NORDISK A/S-SPONS ADR 19.48 302.61B
NVS NOVARTIS AG-SPONSORED ADR 13.54 222.20B
AZN ASTRAZENECA PLC-SPONS ADR 18.8 216.87B
MRK MERCK & CO. INC. 9.99 195.88B
PFE PFIZER INC 7.18 130.67B
SNY SANOFI-ADR 13.71 128.55B
BMY BRISTOL-MYERS SQUIBB CO 6.41 95.71B
GSK GSK PLC-SPON ADR 7.06 78.75B
ZTS ZOETIS INC 26.91 72.25B
HLN HALEON PLC-ADR 22.57 49.87B

About NUVB

Company Profile

NUVB logo image Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The firm is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. The company is conducting Phase I/II study of NUV-1511.

Company Info

NUVATION BIO INC

357 Tehama Street, Floor 3

San Francisco CALIFORNIA 94103 US

CEO: David Hung

Employees: 220

NUVB Company Website

NUVB Investor Relations

Phone: 14157543517

NUVATION BIO INC / NUVB FAQ

What is the stock price of NUVATION BIO INC today?

The current stock price of NUVB is 2.25 USD. The price increased by 10.84% in the last trading session.


What is the ticker symbol for NUVATION BIO INC stock?

The exchange symbol of NUVATION BIO INC is NUVB and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NUVB stock listed?

NUVB stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NUVATION BIO INC stock?

13 analysts have analysed NUVB and the average price target is 7.99 USD. This implies a price increase of 255.11% is expected in the next year compared to the current price of 2.25. Check the NUVATION BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NUVATION BIO INC worth?

NUVATION BIO INC (NUVB) has a market capitalization of 764.26M USD. This makes NUVB a Small Cap stock.


How many employees does NUVATION BIO INC have?

NUVATION BIO INC (NUVB) currently has 220 employees.


What are the support and resistance levels for NUVATION BIO INC (NUVB) stock?

NUVATION BIO INC (NUVB) has a support level at 2.2 and a resistance level at 2.32. Check the full technical report for a detailed analysis of NUVB support and resistance levels.


Is NUVATION BIO INC (NUVB) expected to grow?

The Revenue of NUVATION BIO INC (NUVB) is expected to grow by 594.71% in the next year. Check the estimates tab for more information on the NUVB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NUVATION BIO INC (NUVB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NUVATION BIO INC (NUVB) stock pay dividends?

NUVB does not pay a dividend.


When does NUVATION BIO INC (NUVB) report earnings?

NUVATION BIO INC (NUVB) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of NUVATION BIO INC (NUVB)?

NUVATION BIO INC (NUVB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).


What is the Short Interest ratio of NUVATION BIO INC (NUVB) stock?

The outstanding short interest for NUVATION BIO INC (NUVB) is 13.37% of its float. Check the ownership tab for more information on the NUVB short interest.


NUVB Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is a bad performer in the overall market: 73.98% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NUVB Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NUVB. While NUVB seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NUVB Financial Highlights

Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS decreased by -96.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -123.13%
ROE -144.56%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-128.57%
Sales Q2Q%N/A
EPS 1Y (TTM)-96.77%
Revenue 1Y (TTM)N/A

NUVB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to NUVB. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -30.95% and a revenue growth 594.71% for NUVB


Ownership
Inst Owners59.63%
Ins Owners25.33%
Short Float %13.37%
Short Ratio10.09
Analysts
Analysts84.62
Price Target7.99 (255.11%)
EPS Next Y-30.95%
Revenue Next Year594.71%